581 abstracts found.



Results filter

Final DFS results of the SCOT study: An international Phase III Randomised (1:1) Non-inferiority Trial Comparing 3 months vs 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer

Year:

Session type:

Theme:

Timothy Iveson1,Rachel S Kerr2,Mark P Saunders3,Jim Cassidy4,Niels Henrik Hollander5,Josep Tabernero6,Andrew Haydon7,Bengt Glimelius8,Andrea Harkin4,Karen Allan4,John McQueen4,Claire Scudder9,Kathleen Anne Boyd10,Andrew Briggs10,David Propper11,John Bridgewater12,Ashraf Azzabi13,David Farrugia14,Andrew Webb15,David Cunningham16,Tamas Hickish17,Andrew Weaver18,Simon Gollins19,Harpreet S Wasan20,James Paul4
1University Hospital Southampton,2University of Oxford, Department of Oncology, Oxford,3The Christie Hospital, Manchester,4Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow,5Zealand University Hospital, Department of Oncology and Palliative Care, Rǻdmandsengen 5, DK 4700, Naestved,6Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona,7Australasian Gastro-Intestinal Trials Group (AGITG),8University of Uppsala,9OCTO, University of Oxford, Department of Oncology, Oxford,10Institute of Health and Wellbeing, University of Glasgow, Glasgow,11Barts Cancer Institute, Queen Mary, University of London, London,12University College London, London,13Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle,14Gloucestershire Oncology Centre, Cheltenham General Hospital,15Brighton and Sussex University Hospital Trust, Brighton,16Royal Marsden, London UK (funded by NIHR BRC at the Royal Marsden),17Poole Hospital/Bournemouth University, Bournemouth,18Department of Oncology, Oxford University Hospitals Foundation Trust, Oxford,19North Wales Cancer Treatment Centre, Rhyl,20Hammersmith Hospital, Imperial College London, London

Combined analysis of the FOXFIRE prospective randomised studies of first-line selective internal radiotherapy in patients with liver metastases from colorectal cancer

Year:

Session type:

Theme:

Ricky Sharma1,Peter Gibbs2,E. Anne Francis3,Sarah Pearson4,Sharon Love5,Joanna Moschandreas5,Peter Dutton5,Pradeep S. Virdee5,Val Lewington6,Greg Wilson7,Paul Tait8,Nas Khan9,Dave Berry10,Andy Wotherspoon11,Bruno Morgan12,Ian Chau13,Amir Montazeri14,Daniel Swinson15,Ewan Brown16,Sarah Lowndes17,Paul Ross18,Joanne Hornbuckle19,Alastair Gray20,Guy van Hazel21,Harpreet Wasan22,FOXFIRE, SIRFLOX and FOXFIRE-Global trial investigators FOXFIRE, SIRFLOX and FOXFIRE-Global trial investigators23
1University College London,2Western Hospital, Footscray, Victoria,3Oncology Clincal Trials Office, Department of Oncology, University of Oxford,4Oncology Clinical Trials Office, Department of Oncology, University of Oxford,5Centre for Statistics in Medicine, University of Oxford,6Nuclear Medicine Department, Guy's Hospital, King's College London,7The Christie NHS Foundation Trust,8Imperial College London,9Royal Marsden and Chelsea & Westminster Hospital,10University Hospital Southampton,11The Royal Marsden NHS Foundation Trust,12University of Leicester,13Royal Marsden Hospital, London and Surrey,14The Clatterbridge Cancer Centre NHS foundation Trust, Wirral,15Leeds Teaching Hospital NHS Trust,16Edinburgh Cancer Centre, Western General Hospital, Edinburgh,17Great Western Hospitals NHS Foundation Trust Great Western Hospital, Swindon,18Guy's & St Thomas' NHS Foundation Trust, London,19Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield,20Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford,21University of Western Australia, Perth,22Imperial College Healthcare NHS Trust & Imperial College,23University of Oxford

Stromal/leukocyte crosstalk in immunity and tumour progression

Year:

Session type:

Theme:

Sophie Acton1
1University College London

Development and validation of a 28-gene hypoxia signature for localised prostate cancer

Year:

Session type:

Theme:

Lingjian Yang1,Darren Roberts1,Mandeep Takhar2,Nicholas Erho2,Vinayak Bhandari3,Becky Bibby1,Wei-Chen Cheng4,Syed Haider4,Amy McCorry5,Darragh McArt5,Suneil Jain5,Mohammed Alshalalfa2,Ashley Ross6,Edward Schaffer7,Robert Den8,R. Jeffrey Karnes9,Eric Klein10,Peter Hoskin11,Alastair Lamb12,David Neal4,Francesca Buffa4,Robert Bristow13,Paul Boutros3,Elai Davicioni2,Ananya Choudhury1,Catharine West1
1University of Manchester,2GenomeDX,3Ontario Institute for Cancer Research,4University of Oxford,5Queen’s University Belfast,6Johns Hopkins Medical Institutions,7Northwestern Feinberg School of Medicine,8Sidney Kimmel Medical College at Thomas Jefferson University,9Mayo Clinic Rochester,10Cleveland Clinic,11Mount Vernon Cancer Centre,12University of Cambridge,13University of Toronto

THE REPORT OF THE BLOODWISE TAP CLARITY STUDY COMBINING IBRUTINIB AND VENETOCLAX IN RELAPSED, REFRACTORY CLL SHOWS ACCEPTABLE SAFETY AND PROMISING EARLY INDICATIONS OF EFFICACY

Year:

Session type:

Theme:

Peter Hillmen1,Andrew Rawstron2,Talha Munir3,Kristian Brock4,Samuel Muñoz-Vicente4,Yolande Jefferson4,Rebecca Bishop4,Christopher Fox5,John Gribben6,Adrian Bloor7,Anna Schuh8,Francesco Forconi9,Francesca Yates 4

1Leeds Teaching Hospitals NHS Trust,2HMDS, St. James’s Institute of Oncology,3St James’s University Hospital,4University of Birmingham,5Nottingham City Hospital,,6Barts Cancer Institute, Queen Mary University of London,7University of Manchester,8University of Oxford,9University of Southampton


Quality of life in patients with liver metastases from colorectal cancer treated with first-line selective internal radiotherapy (SIRT): EQ-5D, EORTC QLQ-C30 and LMC21 results from the FOXFIRE study

Year:

Session type:

Theme:

Jane Wolstenholme1,Francesco Fusco2,Alastair Gray2,Ian Chau3,Luise Dunham4,Anne Roberts5,Sharon Love6,Joanna Moschandreas6,Pradeep Virdee6,Guy Van Hazel7,Peter Gibbs8,Val Gebski9,Val Lewington10,Gregory Wilson11,Paul Tait12,Nasir Khan13,David Berry14,Andrew Wotherspoon15,Bruno Morgan16,Sarah Pearson17,Anne Francis17,Adil Al-Nahhas18,Harpreet Wasan18,Ricky Sharma19
1University of Oxford,21Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford,3Royal Marsden Hospital,4Oncology Clinical Trials Office, University of Oxford,5Addenbrooke’s Hospital, Cambridge Cancer Trials Centre,6Centre for Statistics in Medicine, University of Oxford,7University of Western Australia,8Western Hospital,9NHMRC Clinical Trials Centre, University of Sydney,10Nuclear Medicine Department, Guy's Hospital,11The Christie NHS Foundation Trust, Manchester,12Radiology, Imperial College Healthcare NHS Trust & Imperial College,13Radiology, Royal Marsden and Chelsea & Westminster Hospital,14Department of Surgery, University Hospital Southampton,15The Royal Marsden NHS Foundation Trust,16Radiology, University of Leicester,17Oncology Clinical Trials Office, Department of Oncology, University of Oxford,18Imperial College Healthcare NHS Trust & Imperial College,19UCL Cancer Institute, NIHR University College London Hospitals Biomedical Research Centre

National Cancer Diagnosis Audit: initial results

Year:

Session type:

Theme:

Ruth Swann1,Brian Shand2,Jana Witt3,Georgios Lyratzopoulos4,Sara Hiom3,Greg Rubin5,Sean McPhail2
1Health Data Insight (CRUK-PHE Partnership),2Public Health England,3Cancer Research UK,4University College London,5University of Durham

Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study

Year:

Session type:

Theme:

Aurora Perez Cornago1,Timothy J. Key1,Naomi E. Allen1,Georgina K. Fensom1,Kathryn E. Bradbury1,Richard M. Martin2,Ruth C. Travis1
1University of Oxford,2University of Bristol

Rectal and bladder dose-volume relationships during image-guided radiotherapy for prostate cancer

Year:

Session type:

Theme:

Hemal Ariyaratne1,Roberto Alonzi2
1Royal Free NHS Foundation Trust,2Mount Vernon Cancer Centre

Immunohistochemical assessment of cellular proliferation marker Ki67 in relation to prostate radiotherapy fractionation and prognosis in Trans-CHHiP.

Year:

Session type:

Theme:

Anna Wilkins1
1Institute of Cancer Research, LONDON

Predicting lung fitness for radiotherapy from a CT scan

Year:

Session type:

Theme:

Iain Phillips1,Mohammad Hussein1,Veni Ezhil1,Sheaka Alobaidli2,Mazhar Ajaz1,Christopher South1,Andrew Nisbet1,Philip Evans2
1Royal Surrey County Hospital,2University of Surrey

Patient weight loss and shrinkage during radical radiotherapy for head and neck cancer (HNC) does not increase risk of higher spinal cord dose.

Year:

Session type:

Theme:

David Noble1,Ping Lin Yeap2,Shannon Seah2,Karl Harrison2,Marina Romanchikova3,Amy M Bates4,Zheng Lynn5,Simon J Thomas3,Neil G Burnet1
1Cambridge University, Department of Oncology,2Cavendish Laboratory, University of Cambridge,3Department of medical physics, Addenbrooke's Hospital,4Clinical trials unit, Addenbrooke's Hospital,5Cambridge University, School of Clinical Medicine

Integration of validated protein biomarkers within Molecular Pathology Diagnostic Service: the challenges

Year:

Session type:

Theme:

Phillippe Taniere1
1University Hospital Birmingham

PARP inhibitor resistance and acquired vulnerability in ovarian cancer

Year:

Session type:

Theme:

Alan D'Andrea1
1Dana-Farber Cancer Institute

Phosphorylation-dependent assembly of DNA damage response complexes

Year:

Session type:

Theme:

Laurence Pearl1
1University of Sussex

The clinical use of protons in UK: Establishing an evidence based framework

Year:

Session type:

Theme:

Adrian Crellin1
1NIHR Cancer Research Network (NCRN)

Selection of patients for clinical trials in proton therapy – the model-based approach

Year:

Session type:

Theme:

Cai Grau1
1Danish Centre for Particle Therapy

The evolutionary history of 2,658 cancers

Year:

Session type:

Theme:

Moritz Gerstung1
1European Bioinformatics Institute EMBL-EBI

An ultra-high resolution view of clonal evolution

Year:

Session type:

Theme:

Jamie Blundell1
1University of Cambridge

Developing immune stratification for cancer: targeting the tumour microenvironment

Year:

Session type:

Theme:

Gareth Thomas1
1University of Southampton

A leader with good emotional Intelligence makes a positive difference to supporting a worker after a cancer diagnosis

Year:

Session type:

Theme:

Fehmidah Munir1
1Loughborough University

Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial

Year:

Session type:

Theme:

Philippa Corrie1,Andrea Marshall2,Paul Nathan3,Paul Lorigan4,Martin Gore5,Saad Tahir6,Guy Faust7,Charles Kelly8,Maria Marples9,Sarah Danson10,Ernest Marshall11,Stephen Houston12,Ruth Board13,Ashita Waterston14,Jenny Nobes15,Mark Harries16,Satish Kumar17,Gemma Young1,Emily Barker1,Janet Dunn18,Mark Middleton19
1Cambridge Cancer Trials Centre, Addenbrooke's Hospital, Cambridge,2Warwick Clinical Trials Unit, University of Warwick, Coventry,3Medical Oncology, Mount Vernon Hospital, Northwood, Middlesex,4University of Manchester and Christie NHS Foundation Trust, Manchester,5Royal Marsden Hospital NHS Trust, London,6Oncology Research, Broomfield Hospital, Chelmsford,7Oncology Department, Leicester Royal Infirmary, Leicester,8Sir Bobby Robson Cancer Trials Research Centre, Freeman Hospital, Newcastle upon Tyne,9St James’s Institute of Oncology, St James’s University Hospital, Leeds,10Academic Unit of Clinical Oncology, Sheffield Experimental Cancer Medicine Centre, University of Sheffield, Weston Park Hospital, Sheffield,11Cancer & Palliative Care, St. Helen’s Hospital, St. Helens,12Oncology Department, Royal Surrey County Hospital, Surrey,13Rosemere Cancer Centre, Royal Preston Hospital, Preston,14Clinical Trials Unit, Beatson WOS Cancer Centre, Glasgow,15Dept of Clinical Oncology, Norfolk & Norwich University Hospital, Norwich,16Guy’s & St. Thomas’ Hospital, London,17Velindre Cancer Centre, Cardiff,18University of Warwick,19Oxford NIHR Biomedical Research Centre, Oxford

The NCRI Myeloma XI study: a large adaptive randomised clinical trial successfully answering a diverse range of key questions in multiple myeloma.

Year:

Session type:

Theme:

Walter Gregory1,Graham Jackson2,Charlotte Pawlyn3,David Cairns1,Alina Striha1,Anna Waterhouse1,John Jones3,Bhuvan Kishore4,Mamta Garg5,Cathy Williams6,Kamaraj Karunanithi7,Jindriska Lindsay8,Matthew Jenner9,Gordon Cook1,Martin Kaiser3,Mark Drayson10,Roger Owen11,Nigel Russell12,Faith Davies13,Gareth Morgan14
1University of Leeds,2University of Newcastle,3The Institute of Cancer Research, London,4Department of Haematology and Stem Cell Transplantation, Heart of England NHS Foundation Trust, Birmingham,5Leicester Royal Infirmary,6Nottingham University Hospital,7University Hospital of North Midlands, Stoke-on-Trent,8East Kent Hospitals University NHS Foundation Trust,9University Hospital Southampton NHS Foundation Trust,10University of Birmingham,11Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds,12Department of Haematology, Nottingham University Hospitals NHS Trust,13,14Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR

Adjuvant capecitabine for biliary tract cancer (BTC): The UK BILCAP randomized study

Year:

Session type:

Theme:

John Bridgewater1,Richard Fox2,Daniel Palmer3,Raj Prasad4,Darius Mirza5,Alan Anthoney6,Pippa Corrie7,Stephen Falk8,Harpreet Wasan9,Paul Ross10,Lucy Wall11,Jonathan Wadsley12,Jeff Evans13,Deborah Stocken2,Raaj Praseedom7,David Cunningham14,James Garden15,Clive Stubbs2,Juan Valle16,John Primrose17
1UCL,2Cancer Research UK Clinical Trials Unit, University of Birmingham,3University of Liverpool,4University of Leeds,5QE Hospital & Birmingham Children's Hospital,6Leeds Teaching Hospitals NHS Trust,7Addenbrooke's Hospital NHS Trust,8University Hospitals Bristol,9Imperial Healthcare NHS Trust,10Guys and St Thomas’ NHS Trust,11Lothian NHS Trust,12jonathan.wadsley@sth.nhs.uk,13Beatson Institute,14Royal Marsden NHS Trust,15University of Edinburgh,16The Christie,17University of Southampton

Perioperative chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: mature analysis of overall survival in the New EPOC randomised controlled trial

Year:

Session type:

Theme:

John Bridgewater1,Siân Pugh2,Amy Whitehead3,Louise Stanton3,Zina Eminton3,Jane Mellor3,Alex Allen3,Meg Finch-Jones4,Stephen Falk4,Tim Iveson5,Myrddin Rees6,Juan Valle7,Jo Hornbuckle8,Tamas Hickish9,David Cunningham10,Tim Maughan11,O James Garden12,Gareth Griffiths3,John Primrose2,New EPOC Investigators3
1University College London,2University of Southampton,3Southampton Clinical Trials Unit,4University Hospitals Bristol NHS Foundation Trust,5University Hospital Southampton NHS Foundation Trust,6Hampshire Hospitals NHS Foundation Trust,7The Christie NHS Foundation Trust,8Sheffield Teaching Hospitals NHS Foundation Trust,9Poole Hospital and Bournemouth University,10The Royal Marsden Hospital NHS Foundation Trust,11CRUK/MRC Oxford Institute for Radiation Oncology,12The University of Edinburgh

Results of the OPARATIC trial: a phase I dose escalation study of olaparib in combination with temozolomide (TMZ) in patients with relapsed glioblastoma (GBM)

Year:

Session type:

Theme:

Anthony Chalmers1,Garth Cruickshank2,Laurence Dunn3,Sara Erridge4,Lisa Godfrey5,Christopher Herbert6,Sarah Jefferies7,Juanita Lopez8,Catherine McBain9,Marc Pittman5,Rebecca Sleigh10,Colin Watts11,Mark Webster-Smith5,Sarah Halford5
1Glasgow Centre for Cancer Research,2University of Birmingham,3University of Glasgow,4University of Edinburgh,5Cancer Research UK,6University Hospitals Bristol NHS Foundation Trust,7Cambridge University Hospitals NHS Trust,8Institute of Cancer Research,9The Christie NHS Foundation Trust,10LGC,11University of Cambridge

What works and what doesn’t in cancer pain: A summary of recent clinical trial evidence

Year:

Session type:

Theme:

Mike Bennett1
1University of Leeds

Pathophysiology of Cancer Associated Thrombosis

Year:

Session type:

Theme:

Simon Noble1
1Cardiff University

Engineering T cells for pediatric cancer immunotherapy

Year:

Session type:

Theme:

Stephen Gottschalk1
1St Jude Children's Research Hospital

The case for no surgery

Year:

Session type:

Theme:

David Sebag-Montefiore1
1St James' University Hospital

The case for robotics

Year:

Session type:

Theme:

Mark Gudgeon1
1Frimley Park Hospital

Cancer evolution across multiple tumour types

Year:

Session type:

Theme:

David Wedge1
1University of Oxford

Deep and dense data in cancer imaging

Year:

Session type:

Theme:

Julia Schnabel1
1King's College London

Defining the mechanisms and biomarkers of PDGFR inhibitor resistance and response

Year:

Session type:

Theme:

Paul Huang1
1The Institute of Cancer Research

Working after a diagnosis of cancer: Why is it important and how can we support it?

Year:

Session type:

Theme:

Angela de Boer1
1Academic Medical Center

Simulated low dose cone beam CT (CBCT) in paediatric patients

Year:

Session type:

Theme:

Abigail Bryce-Atkinson1,Gillian Whitfield2,Marcel van Herk1
1University of Manchester,2The Christie NHS Foundation Trust

Metastatic Colorectal Cancer (mCRC) Patient Derived Organoids (PDOs) as a preclinical tool to understand mechanisms of resistance to anti-angiogenic drugs

Year:

Session type:

Theme:

Somaieh Hedayat1,George Vlachogiannis1,Yann Jamin1,Khurum Khan2,Javier Fernandez-mateos1,Jens C Hahne1,Michaela Rata2,Dow-Ku Koh2,Nina Tunariu2,David Collins3,Monia Bali3,Ian Chau3,Sheela Rao3,David Watkins3,Naureen Sterling3,Nicos Fotoadis3,Ian Huntingford1,Ruwaida Gegum3,Isma Rana3,Massimo Rugge4,Chiara Braconi1,Matteo Fassan4,Suzanne Eccles1,Simon P Robinson1,David Cunningham3,Nicola Valeri1
1Institute of Cancer Research,2Institute of Cancer Research and Royal Marsden Hospital,3Royal Marsden Hospital,4Padua University

Patient-derived organotypic 3D cultures from tissue and liquid biopsies reflect intra-tumor heterogeneity in advanced prostate cancer

Year:

Session type:

Theme:

Veronica Gil1,Maryou Lambros2,Mateus Crespo2,Ines Figueiredo2,Ana Ferreira2,Ruth Riisnaes2,Daniel Nava Rodrigues2,Rui Neves3,Susana Miranda2,Gemma Fowler2,Semini Sumanasuriya4,Berni Ebbs2,Rita Pereira2,Penny Flohr2,George Seed2,Wei Yuan2,Claudia Bertan2,Suzanne Carreira2,Joaquin Mateo4,Nikolas Stoecklein3,Gunther Boysen2,Johann S. De Bono4
1ICR,2Division of Clinical Studies, Cancer Biomarkers Team, The Institute of Cancer Research, Sutton,3Department of General, Visceral and Pediatric Surgery, University Hospital of the Heinrich-Heine-University, Düsseldorf,4Prostate Cancer Targeted Therapy Group, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton

Phenotypic screening for novel antibody targets in the tumour microenvironment

Year:

Session type:

Theme:

Sandrine Legg1
1MedImmune Ltd

The Breast Cancer Weight Loss (BWEL) Trial

Year:

Session type:

Theme:

Jennifer Ligibel1
1Dana-Farber Cancer Institute

Physical activity and common cancers: From prevention to survivorship

Year:

Session type:

Theme:

John Saxton1
1Northumbria University

Molecular classification of pediatric brain tumors identifies new brain tumor entities

Year:

Session type:

Theme:

Marcel Kool1
1German Cancer Research Center DKFZ

Targeting MYC/MYCN by inhibition of checkpoint kinase 1 (CHK1) sensitises paediatric glioblastoma (pGBM) cells to temozolomide

Year:

Session type:

Theme:

Meera Nandhabalan1
1Institute of Cancer Research

Metabolic requirements of prostate cancer pathogenesis and progression

Year:

Session type:

Theme:

Arkaitz Carracedo Perez1
1CIC bioGUNE

Heterocellular metabolic crosstalk in pancreatic tumors

Year:

Session type:

Theme:

Costas Lyssiotis1
1University of Michigan

Breast symptoms and the risk of subsequent interval cancers and lethal breast cancers

Year:

Session type:

Theme:

Deependra Singh1,Ahti Anttila2
1University of Tampere,2Finnish Cancer Registry

New genetic testing delivery model for breast cancer patients

Year:

Session type:

Theme:

Nazneen Rahman1,Alice Turnbull2,Angela George3,Ann Strydom2,Zoe Kemp3
1Institute of Cancer Research, London and Royal Marsden Hospital,2Institute of Cancer Research, London,3Royal Marsden NHS Foundation Trust

A murine model displaying human BRCAness characteristics based on molecular and tumour infiltrating lymphocyte patterns

Year:

Session type:

Theme:

Fernanda Kyle1,Hasan Mirza1,Rebecca Marlow1,Erika Francesch-Domenech1,Adam Laing1,Guisy Tornillo2,Ramsay Singer1,Patricia Gazinska1,Soizic Garaud3,Karen Willard-Gallo3,Matthew Smalley2,Anita Grigoriadis1,Adrian Hayday1,Andrew Tutt1
1King’s College London,2University of Cardiff,3Institut Jules Bodret

Pan-cancer estimation of tumour purity and stromal composition reveals genomic drivers of immune evasion

Year:

Session type:

Theme:

Tim Fenton1,Ankur Chakravarthy2,Andrew Furness3,Kroopa Joshi3,Ehsan Ghorani3,Matthew Ward4,Emma King4,Matt Lechner5,Tara Marafioti6,Sergio Quezada3,Gareth Thomas4,Andrew Feber5
1University of Kent,2Princess Margaret Cancer Centre, Toronto,3Department of Haematology, UCL Cancer Institute, University College London,4Cancer Sciences Unit, University of Southampton,5Department of Cancer Biology, UCL Cancer Institute, University College London,6t.marafioti@ucl.ac.uk

A microenvironment secretome screen reveals FGF2-mediated resistance to anti-estrogens and PI3K/mTOR inhibitors in ER+ breast cancer

Year:

Session type:

Theme:

Kevin Shee1,John W. Hinds1,Wei Yang1,Riley A. Hampsch1,Kishan Patel1,Frederick S. Varn1,Chao Cheng1,Nicole Jenkins1,Arminja Kettenbach1,Eugene Demidenko1,Philip Owens1,Claudia Lanari2,Anthony C. Faber3,Todd R. Golub4,Ravid Straussman5,Todd W. Miller1
1Geisel School of Medicine at Dartmouth,2The National Scientific and Technical Research Council,3Virginia Commonwealth University,4The Broad Institute,5The Weizmann Institute of Science